Abingdon Health PLC
LSE:ABDX
Intrinsic Value
Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. [ Read More ]
The intrinsic value of one
ABDX
stock under the Base Case scenario is
17.38
GBX.
Compared to the current market price of 10.5 GBX,
Abingdon Health PLC
is
Undervalued by 40%.
Abingdon Health PLC's market capitalization is 12.8m GBX.
ABDX stock price is 10.5 GBX.
ABDX stock price (10.5 GBX) is 40% less than its Intrinsic Value (17.38 GBX).
ABDX stock (7.67 GBX) is 27% less than its price (10.5 GBX). Open Relative Valuation
ABDX has upside potential of 444% compared to the average analyst price target.
Open Wall St Estimates
ABDX's long-term assets (5m GBP) exceed its long-term liabilties (3m GBP).
ABDX's short-term assets (4m GBP) exceed its short-term liabilties (2m GBP).
ABDX's Revenue has grown by an exceptional 138% over the past 12 months.
ABDX has negative Operating Income for the last twelve months.
ABDX has negative Net Income for the last twelve months.
ABDX's ROE (Return on Equity) for the past 12 months is negative and is equal to -77%.
ABDX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -323%.
ABDX has negative Net Debt. This means that the company has more cash and short-term investments (2m GBP) than debt (911k GBP).
ABDX's D/E (Debt to Equity) is very low and is equal to 0.5.
ABDX has positive Gross Profit for the last twelve months.
ABDX has negative Free Cash Flow for the last twelve months.
ABDX has negative three-year average ROE (Return on Equity): -92%. The company is not efficient at transforming stockholders' equity into net income.
ABDX has negative three-year average ROIC (Return on Invested Capital): -131%. The company is not efficient at using invested capital to generate operating income.
ABDX's Altman Z-Score is very low and is equal to -6.34.
ABDX doesn't generate enough operating income (-3m GBP) to safely cover interest payments on its debt (51k GBP).
Valuation Backtest
Abingdon Health PLC
Run backtest to discover the historical profit from buying and selling
ABDX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Abingdon Health PLC
Balance Sheet Decomposition
Abingdon Health PLC
| Current Assets | 3.8m |
| Cash & Short-Term Investments | 2m |
| Receivables | 1.3m |
| Other Current Assets | 411k |
| Non-Current Assets | 1.1m |
| Long-Term Investments | 15k |
| PP&E | 977k |
| Intangibles | 76k |
| Current Liabilities | 2.1m |
| Accounts Payable | 2m |
| Other Current Liabilities | 97k |
| Non-Current Liabilities | 911k |
| Long-Term Debt | 911k |
Earnings Waterfall
Abingdon Health PLC
|
Revenue
|
5.3m
GBP
|
|
Cost of Revenue
|
-2.3m
GBP
|
|
Gross Profit
|
3.1m
GBP
|
|
Operating Expenses
|
-5.6m
GBP
|
|
Operating Income
|
-2.5m
GBP
|
|
Other Expenses
|
306k
GBP
|
|
Net Income
|
-2.2m
GBP
|
Free Cash Flow Analysis
Abingdon Health PLC
ABDX Profitability Score
Profitability Due Diligence
Abingdon Health PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Abingdon Health PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
ABDX Solvency Score
Solvency Due Diligence
Abingdon Health PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Abingdon Health PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABDX Price Targets Summary
Abingdon Health PLC
According to Wall Street analysts, the average 1-year price target for
ABDX
is 57.12 GBX
with a low forecast of 56.56 GBX and a high forecast of 58.8 GBX.
Shareholder Return
ABDX Price
Abingdon Health PLC
| Average Annual Return | -51.45% |
| Standard Deviation of Annual Returns | 36.69% |
| Max Drawdown | -97% |
| Market Capitalization | 12.8m GBX |
| Shares Outstanding | 121 717 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Abingdon Health PLC
Country
Industry
Market Cap
Dividend Yield
Description
Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. The company is headquartered in York, North Yorkshire and currently employs 151 full-time employees. The company went IPO on 2020-12-15. The firm operates through three segments: Contract Development, Contract Manufacturing and Product Sales. The Contract Development segment comprises development work for third parties and is recognized over time based on a proportion of completion. The Contract Manufacturing segment comprises contract development and manufacturing activities. The Product Sales segment comprises the sale of ABC-19, pocket diagnostic products, progressive rod cone degeneration (PCRD) tests and antibodies for research use. Its products also include Seralite, which includes Free Light Chain (FLC) Serum. The Company’s geographical market include the United Kingdom, the United States/Canada, rest of world (ROW).
Contact
IPO
Employees
Officers
The intrinsic value of one
ABDX
stock under the Base Case scenario is
17.38
GBX.
Compared to the current market price of 10.5 GBX,
Abingdon Health PLC
is
Undervalued by 40%.
You don't have any saved screeners yet
